EGFR and neoplasm: Afatinib, an FDA-approved EGFR inhibitor, was the third highest-scoring drug in the PARIS assay (Fig. 1d) and in consultation with the tumor board it was decided to put the patient on afatinib (150 mg p.o., daily) as monotherapy, since the second highest-scoring drug was experimental and not available for this patient.